Womens Health Investment Outlook 2026

Investment events, women-first longevity and wellness concierge services FIGURE 13 Source: Pitchbook, CapIQ, Crunchbase, Boston Consulting GroupPre-seed/seed Early-stage VC Later -stage VC Other Private funding $ UndisclosedPrivate investment funding deals for women-first longevity and wellness concierge services 53% of deals disclosed funding 0 0 20 4 02040608000 1 3092 5468 716 913Deal Total funding ($M) 2021 2022 2023 2024 Forward signals Demand for women-first longevity services continues to expand as awareness and expectations around midlife and preventive care rise. It has been well documented that current care models make it difficult for women to access appropriate menopause care.96,97,98 Clinically, the integration of AI-enabled hormonal and metabolic diagnostics, biomarker-driven programmes and virtual clinical delivery is extending access and improving personalization at scale.99 Policy momentum is also strengthening globally. For example, in the UK, the Menopause Taskforce is integrating menopause into mainstream health agendas.100 For investors, these policy shifts, along with growing payer recognition, signal a more stable and durable market. Early leaders have secured insurance coverage for menopause visits, positioning these services as core medical care rather than discretionary wellness. At the same time, the share of employers offering menopause- related benefits, including access to specialized clinics, is steadily increasing.101 Payer-backed delivery models represent a pivotal step towards long-term reimbursement and system integration. Reasons for optimism –Large, underserved market: More than 1 billion women globally are transitioning through menopause or post-menopause, with persistent care gaps. –Validated, reimbursable models: Early players have demonstrated that insurance-covered visits for menopause and hormonal health can scale beyond boutique delivery. –Funding momentum: Rapid capital inflows and consolidation trends make women’s health companies attractive targets for acquisition or roll-up. Women’s Health Investment Outlook 28